Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Novartis AG's top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth.